0
0
December 11, 2025
SAN ANTONIO — A new daily pill from Roche has shown the ability to reduce the risk of cancer returning by nearly one-third in women with the most common form of early-stage breast cancer, according to landmark clinical trial results presented Wednesday.
The drug, giredestrant, is the first in a new class of oral medicines to demonstrate superiority over standard hormone therapies that have been the backbone of treatment for more than two decades. The findings, unveiled at the San Antonio Breast Cancer Symposium (SABCS) and simultaneously released by Roche’s Genentech unit, could signal a major shift in how doctors treat early-stage hormone receptor-positive (HR-positive) breast cancer.
Breaking the Standard of Care
The Phase III trial, known as lidERA, followed more than 4,000 patients with early-stage, HR-positive, HER2-negative breast cancer who had undergone surgery. Patients were randomly assigned to receive either giredestrant or a physician’s choice of standard endocrine monotherapy—typically tamoxifen or an aromatase inhibitor like letrozole or anastrozole.
The results were statistically significant: patients taking giredestrant experienced a 30% reduction in the risk of invasive disease recurrence or death compared to those on standard therapy.
“After almost 25 years, a new medicine—giredestrant—has demonstrated superiority over existing endocrine therapies in the curative setting, highlighting its potential as a new standard-of-care,” said Dr. Aditya Bardia, Director of the Breast Oncology Program at UCLA and the study’s principal investigator, during the presentation.
At the three-year mark, 92.4% of patients taking giredestrant remained alive and free of invasive disease, compared to 89.6% of those in the control group. The drug also reduced the risk of the cancer spreading to other parts of the body (distant recurrence) by 31%.
A New Class of Weaponry
Giredestrant belongs to a class of drugs known as oral selective estrogen receptor degraders, or SERDs. While older drugs like tamoxifen block estrogen from attaching to cancer cells, SERDs go a step further by binding to the estrogen receptor and causing it to degrade or break down completely.
This mechanism is designed to be more potent against tumors that feed on estrogen, which accounts for approximately 70% of all breast cancer cases. Until now, the only approved SERD was fulvestrant, which requires painful intramuscular injections in a clinic. Giredestrant offers a more convenient, oral alternative.
“What these data suggest is that giredestrant can become a new standard-of-care endocrine therapy,” Dr. Levi Garraway, Roche’s Chief Medical Officer, said in a statement. He noted that the drug appears particularly effective in the “curative setting”—treating patients early before the cancer has spread, when the chance of a complete cure is highest.
Safety and Side Effects
For any drug intended to be taken daily for years, tolerability is critical. The trial data indicated that giredestrant was generally well-tolerated, with a side effect profile comparable to current treatments.
Common issues like joint pain (arthralgia) and hot flashes occurred at similar rates in both groups. However, the study did note a higher incidence of bradycardia (a slower than normal heart rate) in the giredestrant arm—11.3% versus 3.2% in the control group. Researchers emphasized that the majority of these cases were mild, asymptomatic, and did not require patients to stop taking the drug.
Unlike some other cancer therapies, giredestrant did not show severe visual side effects, a problem that has plagued other experimental oral SERDs in development.
Implications for Patients
For the millions of women diagnosed with HR-positive breast cancer, the fear of recurrence is a constant shadow. While current hormone therapies are effective, resistance can develop over time, and side effects often lead patients to stop taking their medication early.
Dr. Eleanor Travis, a medical oncologist not involved in the study, called the results “a potential game-changer.”
“For two decades, we have relied on the same toolbox of aromatase inhibitors and tamoxifen,” Travis said. “To see a 30% improvement over what we considered the ‘gold standard’ is remarkable. If approved, this gives us a powerful new option to help ensure that once the cancer is gone, it stays gone.”
The findings are particularly relevant for patients with “medium to high risk” disease, who were the focus of the lidERA trial. These patients face a higher statistical likelihood of their cancer returning despite surgery and radiation.
Limitations and Next Steps
While the recurrence data is robust, Roche noted that data on overall survival—whether the drug actually helps patients live longer in total—is still “immature.” However, the company stated there is a “clear positive trend” favoring giredestrant.
The trial is ongoing, and researchers will continue to monitor patients to assess long-term safety and survival benefits. Roche plans to submit the data to health authorities worldwide, including the U.S. Food and Drug Administration (FDA), to seek approval for the drug.
If approved, giredestrant would enter a competitive market but would be the first oral SERD authorized for early-stage breast cancer, giving Roche a significant lead over competitors like AstraZeneca, which is also developing similar therapies.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
-
Study Source: lidERA Breast Cancer Study (Phase III). Presented at the San Antonio Breast Cancer Symposium (SABCS), December 10, 2025.
-
Primary Data: Genentech/Roche Press Release. “Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-Positive Early-Stage Breast Cancer.” December 10, 2025.
